We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Society for Biomolecular Sciences to Hold Conference in Asia

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

“A couple of years ago, the SBS board of directors made a strategic decision to expand the society’s reach internationally by bringing high quality science and networking opportunities to a global membership,” said SBS board member and conference committee Chair, John Wang. “As a first step in this strategy, SBS will establish a presence in China, where the pharmaceutical industry has experienced double-digit growth in the last decade, outpacing the country’s overall economic growth and cultivating a large community of pharmaceutical and biotechnological professionals in the process.”
 
Previously held in North America and Europe, SBS meetings provide a forum for the exchange of knowledge and ideas for scientists who are interested in pre- candidate drug discovery from the pharmaceutical, biotechnology and academic sectors.

In recent years, there has been significant growth within the drug-discovery community in China. Starting with the growth of the CRO sector, many pharmaceutical companies have now established research and development centers in China and there is an emerging and vibrant academic and biotechnology community elsewhere in Asia.

At the first SBS China conference, attendees will hear presentations from leading pharmaceutical companies worldwide and can take advantage of this unique opportunity to network with leaders in the field from Asia, North America and Europe. Additionally, they can explore a vendor exhibition showcasing the latest advances in the applications of novel drug-discovery technologies.